No difference in immunochemotherapy regimens for follicular lymphoma

Hoping to inch towards a consensus on the best treatment approach or a standard of care for patients with advanced-stage follicular lymphoma, the SWOG cancer research cooperative group and Cancer and Leukemia Group B (CALGB) joined forces to see if among a pair of immunochemotherapy regimens, one was better than the other. They presented an abstract of their findings at the recent ASH conference in San Diego.

The Phase III randomized trial involved 526 patients with previously untreated, advanced stage follicular lymphoma. One arm (N=263) received the current, if unofficial, standard of care, six cycles of R-CHOP, while the other arm (N=263) received six cycles of CHOP followed by radioimmunotherapy in the form of tositumomab / iodine I-131, better known as Bexxar.

Grade 4 hematologic toxicities were fairly equal with 36% experiencing them in the R-CHOP arm and 30% in the CHOP-RIT arm.

Researchers concluded that "no statistically significant differences in progression-free survival (PFS), overall survival (OS), or serious toxicities are yet demonstrable with either regimen administered in this trial. However, PFS and OS are outstanding with either of the two regimens."

In other words, more research will be necessary to determine the benefit, if any, of adding RIT to current chemotherapy for this set of patients.

Source

A Phase III Randomized Intergroup Trial (SWOG S0016) of CHOP Chemotherapy Plus Rituximab Vs. CHOP Chemotherapy Plus Iodine-131-Tositumomab for the Treatment of Newly Diagnosed Follicular Non-Hodgkin’s Lymphoma.

More Articles

More Articles

This entry looks at Non Hodgkin's Lymphoma in the lungs, clinically known as pulmonary lymphoma, one of the subtypes of lymphoma. 'Lymphoma' is an...

In order to prevent developing any subtype of lymphoma, it would be helpful to know the causes of lymphoma. Unfortunately, in virtually every case...

BEAM chemotherapy is an acronym representing a small family of combination chemotherapy regimens that are used chiefly as salvage regimens in the...

There are two types of cancer: benign and malignant. Benign cancers are the kind that don't spread and don't threaten one's life. Malignant...

The Erythrocyte Sedimentation Rate (ESR - sometimes called sed rate or sedimentation rate) is a nonspecific screening test for various...

Blood counts can be used to identify disease and monitor patient health during cancer treatments. Though these tests cannot diagnose lymphoma on...

MALT lymphoma is a rare B-cell non-Hodgkin's lymphoma that typically runs an indolent or slow-growing clinical...

Mantle cell lymphoma (MCL) is just one of 50-60 known B-cell subtypes of...

After some of the dust has settled, the thoughts of many new lymphoma patients turn to diet and nutrition. They want to know if, in the past,...

According to a study by Japanese researchers, the SMILE combination chemotherapy protocol is effective against extranodal natural killer/T-cell...

In a perfect world, every case of cancer would respond to, and be cured by first-line therapy. Unfortunately, it is not often the case. This is...

Patients treated with maintenance rituximab had three times longer progression-free survival. This is a summary of an article published in the...

Prednisone is a glucocorticosteroid (a steroid) used in the treatment of many types of cancers. It functions as an anti-inflammatory medicine that...

In 1964, researchers at the National Cancer Institute developed the first combination chemotherapy that cured a...

Since so many chemotherapy agents can affect a patient’s sex drive and fertility, thinking about these issues prior...